MPDL3280A Treatment in Patients With Locally Advance or Metastatic Non-small Cell Lung, Bladder and Triple Negative Breast Cancer After Investigational Imaging
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- 09 Nov 2017 Planned End Date changed from 1 Aug 2017 to 1 Feb 2018.
- 09 Nov 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Feb 2018.
- 10 Jun 2017 Biomarkers information updated